-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 29, the new coronavirus mRNA vaccine independently developed by Siwei (Shanghai) Biotechnology Co.
, Ltd.
(hereinafter referred to as "Siwei") was approved by the State Food and Drug Administration and will carry out clinical trials
.
The iterative vaccine developed by Sri Lanka Microbes was approved for clinical trials this time
.
The vaccine contains the D614G mutation of various new coronavirus variants such as Delta and Omicron in the research and development design.
It has protective efficacy against the current epidemic strains of the new coronavirus and has a certain broad spectrum
.
Sri Lanka Microorganism is one of the first innovative companies in China to carry out mRNA drug research and development and human clinical trials of mRNA tumor precision vaccines
.
The R&D and management team of Sri Lanka has brought together a group of scientists who have returned from overseas, worked in many world-renowned biopharmaceutical companies, and have outstanding academic achievements
.
Sri Lanka has mastered the core technology of mRNA vaccines, and has the exclusive global rights of LPP nano-delivery systems; it has self-developed antigen analysis, prediction, and sequence optimization platforms; it has the key technology/equipment for large-scale production of hundreds of millions of doses of mRNA vaccines per year.
The core patents and key materials have completely achieved domestic substitution
.
At present, SMIC has established modern production plants in Shanghai Zhoupu and Fengxian, which can realize large-scale quantitative production
.
The two plants are expected to produce up to 400 million doses per year
.
In the future clinical trials, Sri Lanka will formulate a scientific and rigorous clinical trial plan, strengthen the quality control of clinical research samples, and report the phased progress of clinical research to the national drug review department in a timely manner
.
During the clinical trial, the company will further improve the process products, improve the process stability, and conduct a systematic and complete production process verification
.
Open reprint welcome to forward to Moments and WeChat groups
